155 related articles for article (PubMed ID: 37828372)
1. MicroRNA-409-5p Inhibits GIST Tumorigenesis and Improves Imatinib Resistance by Targeting KDM4D Expression.
Qiu C; Feng YD; Yang X
Curr Med Sci; 2023 Oct; 43(5):935-946. PubMed ID: 37828372
[TBL] [Abstract][Full Text] [Related]
2. PIK3C2A is a gene-specific target of microRNA-518a-5p in imatinib mesylate-resistant gastrointestinal stromal tumor.
Shi Y; Gao X; Hu Q; Li X; Xu J; Lu S; Liu Y; Xu C; Jiang D; Lin J; Xue A; Tan Y; Shen K; Hou Y
Lab Invest; 2016 Jun; 96(6):652-60. PubMed ID: 26950487
[TBL] [Abstract][Full Text] [Related]
3. miR-125a-5p regulation increases phosphorylation of FAK that contributes to imatinib resistance in gastrointestinal stromal tumors.
Huang WK; Akçakaya P; Gangaev A; Lee L; Zeljic K; Hajeri P; Berglund E; Ghaderi M; Åhlén J; Bränström R; Larsson C; Lui WO
Exp Cell Res; 2018 Oct; 371(1):287-296. PubMed ID: 30149002
[TBL] [Abstract][Full Text] [Related]
4. Histone demethylase KDM4D promotes gastrointestinal stromal tumor progression through HIF1β/VEGFA signalling.
Hu F; Li H; Liu L; Xu F; Lai S; Luo X; Hu J; Yang X
Mol Cancer; 2018 Jul; 17(1):107. PubMed ID: 30060750
[TBL] [Abstract][Full Text] [Related]
5. microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome.
Akçakaya P; Caramuta S; Åhlen J; Ghaderi M; Berglund E; Östman A; Bränström R; Larsson C; Lui WO
Br J Cancer; 2014 Nov; 111(11):2091-102. PubMed ID: 25349971
[TBL] [Abstract][Full Text] [Related]
6. Serum miR-518e-5p is a potential biomarker for secondary imatinib-resistant gastrointestinal stromal tumor.
Kou Y; Yang R; Wang Q
J Biosci; 2018 Dec; 43(5):1015-1023. PubMed ID: 30541960
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-30a targets BECLIN-1 to inactivate autophagy and sensitizes gastrointestinal stromal tumor cells to imatinib.
Chen W; Li Z; Liu H; Jiang S; Wang G; Sun L; Li J; Wang X; Yu S; Huang J; Dong Y
Cell Death Dis; 2020 Mar; 11(3):198. PubMed ID: 32251287
[TBL] [Abstract][Full Text] [Related]
8. microRNA-218 increase the sensitivity of gastrointestinal stromal tumor to imatinib through PI3K/AKT pathway.
Fan R; Zhong J; Zheng S; Wang Z; Xu Y; Li S; Zhou J; Yuan F
Clin Exp Med; 2015 May; 15(2):137-44. PubMed ID: 24706111
[TBL] [Abstract][Full Text] [Related]
9. Identification of critical microRNAs in gastrointestinal stromal tumor patients treated with Imatinib.
Zhang Z; Jiang NY; Guan RY; Zhu YK; Jiang FQ; Piao D
Neoplasma; 2018 Sep; 65(5):683-692. PubMed ID: 30249101
[TBL] [Abstract][Full Text] [Related]
10. miR-148b-3p functions as a tumor suppressor in GISTs by directly targeting KIT.
Wang Y; Li J; Kuang D; Wang X; Zhu Y; Xu S; Chen Y; Cheng H; Zhao Q; Duan Y; Wang G
Cell Commun Signal; 2018 Apr; 16(1):16. PubMed ID: 29661252
[TBL] [Abstract][Full Text] [Related]
11. Imatinib Regulates
Huang WK; Shi H; Akçakaya P; Zeljic K; Gangaev A; Caramuta S; Yeh CN; Bränström R; Larsson C; Lui WO
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638938
[TBL] [Abstract][Full Text] [Related]
12. Nuclear KIT induces a NFKBIB-RELA-KIT autoregulatory loop in imatinib-resistant gastrointestinal stromal tumors.
Hsueh YS; Chang HH; Shan YS; Sun HS; Fletcher JA; Li CF; Chen LT
Oncogene; 2019 Sep; 38(38):6550-6565. PubMed ID: 31363162
[TBL] [Abstract][Full Text] [Related]
13. Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors.
Chen W; Kuang Y; Qiu HB; Cao Z; Tu Y; Sheng Q; Eilers G; He Q; Li HL; Zhu M; Wang Y; Zhang R; Wu Y; Meng F; Fletcher JA; Ou WB
Cancer Res; 2017 Sep; 77(18):5107-5117. PubMed ID: 28760855
[TBL] [Abstract][Full Text] [Related]
14. A Screen for Epigenetically Silenced microRNA Genes in Gastrointestinal Stromal Tumors.
Isosaka M; Niinuma T; Nojima M; Kai M; Yamamoto E; Maruyama R; Nobuoka T; Nishida T; Kanda T; Taguchi T; Hasegawa T; Tokino T; Hirata K; Suzuki H; Shinomura Y
PLoS One; 2015; 10(7):e0133754. PubMed ID: 26214687
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of fibroblast growth factor receptor-signaling sensitizes imatinib-resistant gastrointestinal stromal tumors to low doses of topoisomerase II inhibitors.
Boichuk S; Dunaev P; Galembikova A; Mustafin I; Valeeva E
Anticancer Drugs; 2018 Jul; 29(6):549-559. PubMed ID: 29697413
[TBL] [Abstract][Full Text] [Related]
16. KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors.
Lai S; Wang G; Cao X; Luo X; Wang G; Xia X; Hu J; Wang J
Oncotarget; 2016 Jan; 7(2):1367-79. PubMed ID: 26587973
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-494 downregulates KIT and inhibits gastrointestinal stromal tumor cell proliferation.
Kim WK; Park M; Kim YK; Tae YK; Yang HK; Lee JM; Kim H
Clin Cancer Res; 2011 Dec; 17(24):7584-94. PubMed ID: 22042971
[TBL] [Abstract][Full Text] [Related]
18. MiR-320a downregulation is associated with imatinib resistance in gastrointestinal stromal tumors.
Gao X; Shen K; Wang C; Ling J; Wang H; Fang Y; Shi Y; Hou Y; Qin J; Sun Y; Qin X
Acta Biochim Biophys Sin (Shanghai); 2014 Jan; 46(1):72-5. PubMed ID: 24217767
[TBL] [Abstract][Full Text] [Related]
19. MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours.
Gits CM; van Kuijk PF; Jonkers MB; Boersma AW; van Ijcken WF; Wozniak A; Sciot R; Rutkowski P; Schöffski P; Taguchi T; Mathijssen RH; Verweij J; Sleijfer S; Debiec-Rychter M; Wiemer EA
Br J Cancer; 2013 Sep; 109(6):1625-35. PubMed ID: 23969726
[TBL] [Abstract][Full Text] [Related]
20. miRNA-21 sensitizes gastrointestinal stromal tumors (GISTs) cells to Imatinib via targeting B-cell lymphoma 2 (Bcl-2).
Cao CL; Niu HJ; Kang SP; Cong CL; Kang SR
Eur Rev Med Pharmacol Sci; 2016 Sep; 20(17):3574-81. PubMed ID: 27649657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
